Longitude targeting $525M for third fund

Life science venture firm Longitude Capital has set a $525 million target for its third fund, Longitude Venture Partners III, according to an SEC filing. The firm declined to comment.

Longitude closed its second fund in 2012 with $385 million. The firm's investments include allergy company Aimmune Therapeutics Inc. (NASDAQ:AIMT), neurology play Jazz Pharmaceuticals plc (NASDAQ:JAZZ), and pain company Collegium Pharmaceutical Inc. (NASDAQ:COLL) (see BioCentury, Oct. 15, 2012). ...